NAS
DFTX

Nykredit A/S’s Definium Therapeutics DFTX Stock Holding History

Nykredit A/S’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.5K Buy
+947
New +$23.4K ﹤0.01% 1524

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's DFTX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 947 shares worth $44.5K. The stake represents ﹤0.01% of the portfolio and ranks #1524 among its holdings.

240 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Nykredit A/S held 947 shares of Definium Therapeutics worth $44.5K as of Q2 2026.
  • Definium Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1524 holding.
  • 240 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.